March 26, 2026 by Mohr Marketing
The Digital Edge for Uber and Lyft Assault Lawsuits: How Data Helps Your Uber Sexual Assault Clients Win In rideshare assault litigation, the difference between a difficult case and a dominant one often comes down to what is hiding in the data. While a survivorโs testimony is the heart of the story, digital proof is…
Continue reading Digital Evidence in Uber and Lyft Assault Lawsuits
March 16, 2026 by Mohr Marketing
Safeguarding Your Firmโs Depo-Provera (MDL 3140) Inventory As the pharmaceutical liability landscape shifts toward MDL 3140 (In re: Depo-Provera Products Liability Litigation), many firms are facing a critical operational choice: build volume quickly or build volume correctly. While the potential plaintiff pool for Depo-Provera is massiveโestimated at 74 million women worldwideโthe clinical criteria required to…
Continue reading Building Your MDL 3140 Portfolio with Precision
March 15, 2026 by Mohr Marketing
Donโt settle for “intake noise.” Leverage our Compliance Shield protocol to acquire signed plaintiffs with 12+ months of usage and imaging-confirmed Intracranial Meningiomas. The Opportunity: Why Pfizer (MDL 3140) Now? Massive Solvency: Unlike other defendants, Pfizer holds immense liquidity, ensuring the “muscle” to absorb global settlements. Scientific Catalyst: A March 2024 BMJ study revealed a…
Continue reading Build a High-Value Depo-Provera Docket with Verified, Audit-Ready Retainers
March 14, 2026 by Mohr Marketing
Depo-Provera MDL Science-Back Intake: How We Filter for the “5.6x Risk” Cohort The catalyst for the Depo-Provera MDL was a bombshell study published in the British Medical Journal (BMJ) in March 2024. That study didn’t just suggest a link; it identified a specific 5.6-fold increased risk of developing meningiomas for women using the drug for…
Continue reading Depo-Provera MDL – How We Filter for the “5.6x Risk” Cohort
March 13, 2026 by Mohr Marketing
The $3B Liquidity Advantage: Why Depo-Provera is the Strategic Play for 2025-2026 As many mass torts face defendants with thinning capital, the Depo-Provera litigation stands out for its defendant solvency. Pfizer holds massive liquidity, providing the “muscle” to absorb a global settlement without the existential risks seen in other recent litigations. A Mature Docket with…
Continue reading Why Depo-Provera is the Strategic Play for 2025-2026
March 12, 2026 by Mohr Marketing
Beyond “Intake Noise”: Why Precision is the Only Way to Build a Depo-Provera Docket The pharmaceutical liability landscape has shifted with the emergence of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the numbers are massiveโan estimated 74 million users worldwideโthe legal viability of these cases hinges on a level of medical precision that…
Continue reading Why Precision is the Only Way to Build a Depo-Provera Docket
March 11, 2026 by Mohr Marketing
MDL 3140: Is Your Intake Ready for the Depo-Provera Docket? In an era where some mass tort defendants are thinly capitalized or seeking bankruptcy protection, the Depo-Provera litigation offers a rare strategic advantage: Defendant Solvency. Pfizer, the primary defendant, holds massive liquidity, giving them the “muscle” to absorb a global settlement without existential risk to…
Continue reading Defendant Solvency and the Business Case for MDL 3140
March 10, 2026 by Mohr Marketing
The Precision Mandate: Why Medical Integrity is the Only Path to a Defensible Depo-Provera Docket The pharmaceutical liability landscape shifted significantly with the consolidation of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the sheer scale of the potential plaintiff poolโestimated at 74 million usersโis a headline-grabber, the true story of this litigation lies…
Continue reading Medical Integrity the Only Path to Defensible Depo-Provera Docket
February 28, 2026 by Mohr Marketing
Mohr Marketing Deploys AI WebTrackerยฎ to Target High-Value NAION and Verified Gastroparesis Claims Amid New 2026 Medical Evidence As GLP-1 litigation enters a critical juncture, Mohr Marketing, LLC has announced the deployment of enhanced precision-targeting technologies to assist law firms in securing high-value claims. With federal case counts nearing 3,200 actions in MDL 3094 and…
Continue reading The GLP-1 Litigation Landscape has Shifted
February 26, 2026 by Mohr Marketing
The Compliance Shield: Why Diagnostic Proof is the New Gold Standard To qualify for a claim in the 2026 Ozempic (Semaglutide) MDL, the court now requires specific medical evidence to distinguish drug-induced injuries from pre-existing conditions. Use this checklist to determine if a potential claimant meets the February 2026 court standards for Gastroparesis or NAION.…
Continue reading The 2026 GLP-1 Pivot: Securing High-Value, Verified Retainers